Hepcidin modulation in human diseases: From research to clinic

doi:10.3748/wjg.15.538

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6471)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

418

HTML

5480

Figures (1-2)

291

Tables (1-2)

282

Sum=6471

Feb 7, 2009 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (70)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 7, 2009; 15(5): 538-551
Published online Feb 7, 2009. doi: 10.3748/wjg.15.538

Full Size Figure Download Figure

Figure 1 Typical mass spectra of human serum (A) and urine (B) samples by SELDI-TOF-MS in a control subject. In addition to hepcidin-25, two isoforms truncated at the N-terminus are detectable. The 20 aa isoform is detectable in both urine and serum, while the 22 aa isoform is found only in urine.

Citation: Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human diseases: From research to clinic. World J Gastroenterol 2009; 15(5): 538-551
URL: https://www.wjgnet.com/1007-9327/full/v15/i5/538.htm
DOI: https://dx.doi.org/10.3748/wjg.15.538